Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid … (NCT02465060) | Clinical Trial Compass
Active — Not RecruitingPhase 2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
United States, Guam, Puerto Rico6,452 participantsStarted 2015-08-17
Plain-language summary
This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* ELIGIBILITY CRITERIA FOR SCREENING BIOPSY (STEP 0)
* Patients must be \>= 18 years of age. Because no dosing or adverse event data are currently available on the use of study investigational agents in patients \< 18 years of age, children are excluded from this study
* Patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to registration; patients that are pregnant or breast feeding are excluded; a patient of childbearing potential is anyone, regardless of whether they have undergone tubal ligation, who meets the following criteria:
* Has achieved menarche at some point
* Has not undergone a hysterectomy or bilateral oophorectomy; or
* Has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
* Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse prior to study entry, for the duration of study participation, and for 4 months after completion of study; should a patient or partner of the patient become pregnant or suspect a pregnancy while participating in this study, the treating physician should be informed immediately
* Patients must have histologically documented solid tumors or histologically confirmed diagnosis of lymphoma or multiple myeloma requiring therapy and meet one of the following criteria:
* Patien…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial uses genetic testing to match me to a targeted therapy based on my tumor's specific mutations, can you walk me through what that biopsy or genomic testing process would look like for me, and how likely it is that my tumor would actually match one of the available treatment arms?
2This is a Phase 2 trial focused on measuring objective response rate — meaning how many patients' tumors shrink — so what does the current data suggest about the likelihood of responding to the targeted therapy I might be assigned to, and how does that compare to any standard treatment options still available to me?
3Since the trial is listed as 'active but no longer recruiting,' does that mean there's any realistic pathway for me to still enroll, or should we focus our energy on other options?
4Because my cancer is described as advanced and refractory — meaning it hasn't responded to prior treatments — how would joining this trial affect my ability to pursue other therapies at the same time or immediately afterward if the assigned treatment doesn't work?
5If my tumor undergoes genetic testing and doesn't match any of the trial's targeted treatment arms, what would our next steps be, and is that genomic information still useful for guiding my care outside of this trial?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.